PRESENTATION TITLE
Metabolic Reprogramming in Glioblastoma: Biologic Consequence and Therapeutic Implications

PRESENTER(S)
Prakash Chinnaiyan, M.D.
Professor of Radiation Oncology, CNS Servic Chief, Director of Tumor Metabolism, Oakland University, William Beaumont School of Medicine, Rochester, MI

PRESENTER BIO

Dr. Prakash Chinnaiyan completed his undergraduate studies at the University of Michigan. He then earned his medical degree at Wayne State University and completed residency in Radiation Oncology and post-doctoral laboratory training at the University of Wisconsin-Madison in 2006.  Following residency, he joined the Department of Radiation Oncology at the H. Lee Moffitt Cancer Center in Tampa, Florida, where he was a tenured physician-scientist specializing in the treatment of patients with brain and spine malignancies, serving as Chief of the CNS service and Director of Radiosurgery.  

In 2015, he joined Beaumont’s Department of Radiation Oncology, serving as Chief of the CNS Service, Director of Tumor Metabolism, and Professor at the Oakland University William Beaumont School of Medicine.  Dr. Chinnaiyan is recognized nationally for the treatment of brain tumors.  He is principal investigator of a laboratory funded by the National Institute of Health (NIH) focusing on tumor metabolism and how it contributes towards the aggressive phenotype of these tumors. The overarching goal of his research is translational in nature, with a clear objective of bringing laboratory-based discoveries into the clinic.  Along these lines, he has developed and led several clinical trials in patients with brain tumors, testing novel therapeutic approaches that are largely based on his laboratory findings.  He is an active member in the National Cancer Institute (NCI) Glioblastoma Working Group and the Radiation Therapy Oncology Group (RTOG/NRG) Brain Tumor Committee and served as faculty at the American Society of Therapeutic Radiation Oncology (ASTRO) and Society of Neuro-Oncology (SNO) national meetings.  Dr. Chinnaiyan has authored or co-authored over 100 peer-reviewed manuscripts, abstracts, and book chapters and has been an invited presenter at numerous national meetings.

Dr. Chinnaiyan specializes in treating patients with both malignant and benign disorders of the brain and spine.  He is particularly recognized in the management of patients with low or high-grade glioma, which also represents his primary area of research, proton beam therapy, and stereotactic radiosurgery.

VIEWING LOCATIONS
Zoom Link
LEARNING OBJECTIVES

• Identify specific reasons why clinical gains in GBM have been limited.

• Describe how metabolic reprogramming contributes to gliomagenesis.

• Recognize different strategies designed to therapeutically target metabolic vulnerabilities in glioblastoma.

ATTENDANCE / CREDIT
Text the session code (provided only at the session) to 507-200-3010 within 48 hours of the live presentation to record attendance. All learners are encouraged to text attendance regardless of credit needs. This number is only used for receiving text messages related to tracking attendance. Additional tasks to obtain credit may be required based on the specific activity requirements and will be announced accordingly. Swiping your badge will not provide credit; that process is only applicable to meet GME requirements for Residents & Fellows.

TRANSCRIPT
Any credit or attendance awarded from this session will appear on your Transcript.

For disclosure information regarding Mayo Clinic School of Continuous Professional Development accreditation review committee member(s) and staff, please go here to review disclosures.